Clinical trials: Rivaroxaban
Cirrhosis
Multicenter Prospective Randomized Trial of the Effect of Rivaroxaban on Survival and Development of Complications of Portal Hypertension in Patients With Cirrhosis
The main objective of the study will determine if patients with liver cirrhosis, anticoagulation free survival improves hypertension decompensation portal and / or transplantation without serious side effects.
- Trial name
- CIRROXABAN (NCT02643212)
- Testing
- Rivaroxaban
- Where
- 14 sites in Spain
- Volunteers
- 160 people
- Sponsor
- David Garcia Cinca
Complications; Arthroplasty
Evaluation of Wound Drainage After Knee or Hip Arthroplasty
To compare side effects and complications relating to use of warfarin or rivaroxaban, tolerance and/or toxicity of these two agents such as drop in hemoglobin post operatively, extent of bruising, quantity of wound drainage…
- Trial name
- NCT02054936
- Testing
- Rivaroxaban (Xarelto), Warfarin (Coumadin)
- Where
- United States
- Sponsor
- University of Michigan
Atrial Fibrillation and Flutter
Direct Oral Anticoagulants Pharmacodynamics in Octogenarian Patients With Atrial Fibrillation
Background: The incidence of atrial fibrillation(AF) increases substantially with age and it is estimated that more than one third of AF patients are octogenarians.
- Trial name
- NCT02623049
- Testing
- New oral anticoagulant pharmacodynamic analysis (blood level assesment)
- Where
- 2 sites in Israel
- Volunteers
- 150 people
- Sponsor
- Rabin Medical Center
Atrial Fibrillation
Perioperative Anticoagulant Use for Surgery Evaluation Study
The aim of the Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study, is to establish a safe, standardized protocol for the perioperative management of patients with atrial fibrillation (AF) who are receiving a…
- Trial name
- PAUSE (NCT02228798)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 3,135 people
- Sponsor
- McMaster University
Atrial Fibrillation, Atrial Flutter
Combined Use of BIOTRONIK Home Monitoring and Predefined Anticoagulation to Reduce Stroke Risk
The IMPACT Study will investigate the potential clinical benefit of the combined use of BIOTRONIK Home Monitoring (HM) technology and a predefined anticoagulation plan compared to conventional device evaluation and…
- Conditions
- Atrial Fibrillation, Atrial Flutter, Stroke, Embolism, Systemic Arterial
- Trial name
- IMPACT (NCT00559988)
- Testing
- Home Monitoring Guided OAC, Physician-Directed OAC
- Where
- 80 sites in United States, Australia and 4 more
- Volunteers
- 2,718 people
- Sponsor
- Biotronik, Inc.
Atrial Fibrillation Patients With Intermediate Stroke Risk
The Efficacy and Safety of Non-vItamiN K antaGonist oraL Anticoagulants for intermEdiate Stroke Risk in Patients With Atrial Fibrillation (SINGLE-AF)
Atrial fibrillation (AF) increases the risk of stroke, and oral anticoagulation is strongly recommended for patients at high thromboembolic risk.
- Trial name
- NCT04437654
- Testing
- Anticoagulation group(DOAC group)
- Where
- South Korea
- Volunteers
- 1,803 people
- Sponsor
- Yonsei University
Venous Thromboembolism, Children Under 2 Years
A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)
This is an observational study in which only data are collected from participants receiving their usual treatment. The study is done in children under 2 years old with venous thromboembolism (VTE).
- Trial name
- XAPAEDUS (NCT05900388)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Standard of care (SOC)
- Where
- 4 sites in Denmark, France and 2 more
- Volunteers
- 850 people
- Sponsor
- Bayer
Venous Thrombosis, Pulmonary Embolism
Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Phenprocoumon for the first…
- Conditions
- Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome
- Trial name
- NCT01947959
- Testing
- Rivaroxaban (Xarelto, Bay59-7939), Standard of care
- Where
- Germany
- Volunteers
- 665,533 people
- Sponsor
- Bayer
Atrial Fibrillation
High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns, and safety and effectiveness outcomes in patients with NVAF…
- Trial name
- HELIOS-AF (NCT05038228)
- Testing
- Apixaban, Rivaroxaban, Dabigatran
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer
Cerebral Venous Thrombosis
Study of Rivaroxaban for CeREbral Venous Thrombosis
SECRET examines the safety of rivaroxaban versus standard-of-care for treatment of symptomatic cerebral venous thrombosis, initiated within 14 days of diagnosis.
- Trial name
- SECRET (NCT03178864)
- Testing
- Rivaroxaban, Standard of care
- Where
- 11 sites in Canada
- Volunteers
- 55 people
- Sponsor
- University of British Columbia
Stroke, Systemic Embolism
NOAC Portuguese Real World Study
To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists
- Conditions
- Stroke, Systemic Embolism, Major Bleeding
- Trial name
- NCT04808934
- Testing
- Apixaban, dabigatran, rivaroxaban
- Sponsor
- Pfizer
Ischemic Stroke, Patent Foramen Ovale
Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence
A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke than in control subjects. Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral anticoagulants, and…
- Conditions
- Ischemic Stroke, Patent Foramen Ovale, Atrial Septal Aneurysm, Migraine
- Trial name
- CLOSE (NCT00562289)
- Testing
- aspirin, Antivitamins K or rivaroxaban or dabigatran or apixaban, Devices for PFO closure
- Where
- France
- Volunteers
- 664 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Direct Oral Anticoagulants (DOACs), Oral Surgical Procedures
Oral Biopsy Bleeding in Patients on Direct Oral Anticoagulants (DOACs)
Direct oral anticoagulants (DOACs) are increasingly used, but evidence on bleeding risk during oral soft tissue biopsy is limited.
- Trial name
- DOACS_BX (NCT07520890)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Pisa
Ischemic Stroke, Intracranial Atherosclerotic Disease
Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in Intracranial Atherosclerotic Disease
CATIS-ICAD is a clinical pilot study in which patients who have had a recent ischemic stroke, that is a stroke caused by a blood clot or a narrowing of the blood vessels in the brain due to the build up of plaque, will be…
- Trial name
- NCT04142125
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet bid, Acetylsalicyclic acid 81 mg tablet qd
- Where
- 10 sites in Canada
- Volunteers
- 101 people
- Sponsor
- Population Health Research Institute
Atrial Fibrillation, Atrial Tachycardia
Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.
Catheter ablation of atrial fibrillation (AF) or left atrial tachycardia (GAD) is usually performed in patients treated with vitamin K antagonists (VKAs) or direct oral anticoagulants (DOACs) that are increasingly used.
- Trial name
- FACADO (NCT05802576)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis
Alerting Providers at Patient Hospital Discharge to Consider Prescribing Rivaroxaban to Reduce Venous Thromboembolism
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to…
- Conditions
- Venous Thromboembolic Disease, Pulmonary Embolism and Thrombosis, Deep Vein Thrombosis, Hospitalism
- Trial name
- eVTE (NCT06232551)
- Testing
- EHR (electronic health record) alert, No EHR (electronic health record) alert
- Where
- United States
- Volunteers
- 152,000 people
- Sponsor
- Scott C. Woller, MD
Anemia, Venous Thrombosis
Utilization of TEG to Monitor Rivaroxaban Activity
The invesigators seek to devise a strategy for the assessment of Rivaroxaban activity in trauma and Emergency General Surgery (EGS) patients available as point-of-care testing.
- Trial name
- NCT02651909
- Testing
- blood sampling
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Matthew Neal MD
Cerebral Venous Thrombosis
Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam
This prospective, single-arm observational cohort study aims to evaluate the real-world effectiveness and safety of direct oral anticoagulants (DOACs), specifically dabigatran or rivaroxaban, in patients with cerebral venous…
- Trial name
- DCVT-VN25 (NCT07083609)
- Testing
- Dabigatran, Rivaroxaban
- Where
- Vietnam
- Volunteers
- 69 people
- Sponsor
- Hieu Trung Dinh
Differences in Laboratory Coagulation Parameters
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery.
- Trial name
- NCT00986635
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Peripheral Arterial Disease
The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease
The purpose of this study is to understand how the drug rivaroxaban improves symptoms associated with peripheral artery disease.
- Trial name
- NCT05009862
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81Mg Ec Tab
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Vanderbilt University Medical Center